Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 11/20 | 0.47 |
| ▸ | HTR2B | P41595 | 10/20 | 0.47 |
| ▸ | HTR2A | P28223 | 9/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630341 | 0.79 | EPHX2 (0.47) | EPHX2HTR2CHTR2BHTR2ATRPV1 | |
| SCHEMBL2702455 | 0.79 | EPHX2 (0.56) | EPHX2HTR2CHTR2BHTR2AHSD11B1 | |
| SCHEMBL27831828 | 0.77 | EPHX2 (0.45) | EPHX2HTR2CHTR2BHTR2AHSD11B1 | |
| SCHEMBL20555976 | 0.76 | EPHX2 (0.53) | EPHX2HTR2CHTR2BHTR2AHSD11B1 | |
| SCHEMBL233710 | 0.74 | EPHX2 (1.00) | EPHX2HSD11B1MAPTTSHRHTT | |
| SCHEMBL20555977 | 0.74 | EPHX2 (0.44) | EPHX2HTR2CHTR2BHTR2ATRPV1 | |
| Piperazine SCHEMBL5324447 | 0.73 | EPHX2 (0.97) | EPHX2HSD11B1MAPTTSHRHTT | |
| Hydrochloric Acid SCHEMBL10319192 | 0.73 | EPHX2 (0.97) | EPHX2HSD11B1MAPTTSHRHTT | |
| SCHEMBL5356587 | 0.69 | EPHX2 (0.89) | EPHX2HSD11B1MAPTTSHRHTT | |
| SCHEMBL31245014 | 0.69 | HTR2C (0.50) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335907-B1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB PUBL (SE) | 2010-06-09 | — | — | EP | disclosed |
| US-7247633-B2 | Pyrimidine compounds and their use | BIOVITRUM AB (SE) | 2007-07-24 | — | — | US | disclosed |
| US-7229997-B2 | Compounds and their use | BIOVITRUM AB (SE) | 2007-06-12 | — | — | US | disclosed |
| EP-1506185-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF 5-HT | BIOVITRUM AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| US-20040014767-A1 | Novel compounds and their use | BIOVITRUM AB, A SWEDISH CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20030232814-A1 | Novel compounds and their use | BIOVITRUM AB (PUBL) (SE) | 2003-12-18 | — | — | US | disclosed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-1998033504-A1 | TREATMENT OF URINARY INCONTINENCE | AKZO NOBEL N.V. (NL) | 1998-08-06 | — | — | WO | disclosed |
| EP-0370560-B1 | Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl)-2-pyridinyl] piperazines | AKZO NV (NL) | 1994-01-12 | — | — | EP | disclosed |
| US-4971969-A | NERVOUS SYSTEM DISORDERS | AKZO N.V. (NL) | 1990-11-20 | — | — | US | disclosed |
| US-4971969-A | NERVOUS SYSTEM DISORDERS | AKZO N.V. (NL) | 1990-11-20 | — | — | US | disclosed |
| EP-0370560-A1 | Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl)-2-pyridinyl] piperazines | Akzo Nobel N.V. (NL) | 1990-05-30 | — | — | EP | disclosed |
| EP-0370560-A1 | Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl)-2-pyridinyl] piperazines | Akzo Nobel N.V. (NL) | 1990-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232814-A1 | Novel compounds and their use | GPR119, FABP4, MC4R | EPHX2 1603/4885HTR2C 233/4885HTR2B 356/4885 |
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | EPHX2 323/4885HTR2C 916/4885HTR2B 1039/4885 |
| US-20040014767-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | EPHX2 323/4885HTR2C 916/4885HTR2B 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.